Suze: Why We Don’t Need a Second Royal Commission C-19 Review

My review won’t be submitted because it does not fit the Royal Commission [RC] criteria for submission and I do not believe a more comprehensive review with a new unbiased panel is justified.

Just under $74B was set aside for Covid-19 [C-19] and more than $10M was spent on the Royal Commission enquiry. It makes no sense to throw good money after bad, which is not said to demean the high personal cost paid by thousands of victims of the Labour Government’s C-19 lockdowns and mandates.

But this is the right time to move on with an avalanche of overseas studies providing data not previously available.

Thomas Cranmer: Revealed - NZ Medsafe's Safety Assessment of the Pfizer Vaccine for Pregnant Women

Chris James, Group Manager of Medsafe told in Court by an expert, "It is concerning that public health officials did not reveal this atypical feature of Comirnaty."

As part of New Zealand’s provisional approval of the Pfizer vaccine, the country’s regulator Medsafe prepared a Non-Clinical Assessment in January 2021 which concluded that:

Thomas Cranmer: Pfizer Vaccine Approval in NZ Under Scrutiny - A Retrospective Analysis

The government's enthusiastic promotion of the Pfizer vaccine approval in New Zealand overstated the strength of the clinical assessment despite significant gaps in the data.

The Pfizer vaccine was approved for use by New Zealand’s regulator, Medsafe on 3 February 2021. The development was immediately welcomed by then Prime Minister Ardern who stated, “Medsafe’s decision is the culmination of a rigorous assessment process over many months to ensure the Pfizer/BioNTech vaccine is safe and effective to use here. It is informed by the most up-to-date medical and scientific data. We can have confidence in their decision.”

However, in reality, the government’s representation of Medsafe's assessment was overstated. Specifically, Medsafe’s clinical assessment found: